The Oncolytic Virotherapy Summit is back for its fifth year as the only conference to bring together industry leaders, clinicians and academic experts focused on finding an effective immuno-oncology.
Over 3 days packed with compelling case studies, diverse panels and varied networking opportunities, you'll glean insights from industry and academic leaders. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of oncolytic virus development.
Conference Only : USD 2399.0,
Conference + 1 Workshop: USD 2999.0,
Conference + 2 Workshops: USD 3399.0
Speakers: Lance Weed, Vice President Operations, uniQure, Anton Xavier, Founder, K9 Biotech, Michael Wood MBA, Founder and Chief Operating Officer, OncoMyx, Robert Coffin, CEO, Replimmune, Daniel Katzman, CEO, Unleash Immuno Oncolytics, Dr Erik Digman Wiklund, Chief Business Officer, Targovax ASA, Michael Moore, Vice President Investor Relations and Corporate Communications, Oncolytics Biotech, David Sherris, President and Chief Executive Officer, GenAdam Therapeutics Inc., Louis Cantolupo, Chief Operating Officer, Unleash Immuno Oncolytics, Christophe Quéva, Chief Scientific Officer, Oncorus, Sridhar Pennathur, Senior Director and Fellow Biopharmaceutical Development, AstraZeneca, Dr John Goldberg, Senior Vice President Clinical Development and Practicing Paediatric Oncologist, Oncorus, Brian Haines PhD, Senior Director Pharmacology and Toxicology, Oncorus, Lorena Lerner, Vice President Molecular Biology and Virology, Oncorus, Beatriz Mesa, Senior Director Oncolytic Virus Manufacturing, Sorrento Therapeutics, Steve Thorne, Chief Scientific Officer, Western Oncolytics, Shara Dellatore, Principal Scientist and Group Leader, Merck, Angelica Loskog, CEO, Lokon Pharma, Maritza McIntyre, Former Chief Gene Therapy Branch, FDA